A Phase 1 Open-Label, Multiple Dose, Two Part Dose Escalation Study of ECP-1014 as a Treatment for Patients With Solid Tumor Cancers
Latest Information Update: 17 Feb 2023
At a glance
- Drugs ECP-1014 (Primary)
- Indications Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Euclises Pharmaceuticals
- 14 Feb 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Aug 2021 to 1 May 2023.
- 14 Feb 2023 Planned End Date changed from 1 Aug 2022 to 1 Dec 2023.
- 14 Feb 2023 Planned primary completion date changed from 1 Jun 2022 to 1 Sep 2023.